EOS imaging : Filing of the 2013 Annual Financial Report

Regulatory News:

EOS Imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced the filing of its 2013 Annual Financial Report.

The Annual Financial Report is now available to the public, and has been registered with the Autorité des marchés financiers.

The Annual Financial Report is available at the registered office of the company (10 rue Mercœur - 75011 Paris) and on the EOS imaging’s website at www.eos-imaging.com in the section "Investors / Documentation / Financial Reports”.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit www.eos-imaging.com.

About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1^st half of 2014, on July 22, 2014 (after market).